Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with Cerebrolysin.

D W Molloy1, T I Standish

  • 1Geriatric Research Group, McMaster University Department of Medicine, Hamilton, Ontario, Canada.

Journal of Neural Transmission. Supplementum
|August 29, 2000
PubMed
Summary

Cerebrolysin, a neurotrophic drug, shows long-term effectiveness in treating Alzheimer's disease. Repeat treatments with Cerebrolysin may help maintain patient function over extended periods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing.

Translational medicine @ UniSa·2019
Same author

Five short screening tests in the detection of prevalent delirium: diagnostic accuracy and performance in different neurocognitive subgroups.

International journal of geriatric psychiatry·2016
Same author

Measuring the Effect of Carers on Patients' Risk of Adverse Healthcare Outcomes Using the Caregiver Network Score.

The Journal of frailty & aging·2016
Same author

Components of the Risk Instrument for Screening in the Community (RISC) that Correlate with Public Health Nurses' Perception of Risk.

The Journal of frailty & aging·2016
Same author

The Community Assessment of Risk Instrument: Investigation of Inter-Rater Reliability of an Instrument Measuring Risk of Adverse Outcomes.

The Journal of frailty & aging·2016
Same author

Nurses' preferred end-of-life treatment choices in five countries.

International nursing review·2013

Area of Science:

  • Neuroscience
  • Pharmacology
  • Geriatrics

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Current treatments offer limited long-term efficacy.
  • Cerebrolysin exhibits neurotrophic properties in preclinical models.

Purpose of the Study:

  • To evaluate the long-term clinical efficacy and safety of Cerebrolysin in Alzheimer's disease patients.
  • To provide evidence supporting repeat treatment strategies for sustained functional maintenance.

Main Methods:

  • Clinical experience from a double-blind, placebo-controlled trial.
  • Data from a subsequent compassionate use program.
  • Positron Emission Tomography (PET) study to assess treatment effects.

Main Results:

  • Cerebrolysin demonstrated a favorable safety profile.
  • Evidence suggests sustained functional benefits with repeat Cerebrolysin treatments.
  • Long-term efficacy in managing Alzheimer's disease symptoms was observed.

Conclusions:

  • Cerebrolysin is a safe and effective therapeutic option for Alzheimer's disease.
  • Repeat administration of Cerebrolysin may be crucial for long-term patient management.
  • Further research into long-term treatment protocols is warranted.

Related Experiment Videos